WALTHAM, Mass., Nov. 20, 2017 -- TESARO, Inc., an oncology-focused biopharmaceutical company, is proud to announce that co-founders Lonnie Moulder, CEO, and Mary Lynne Hedley, Ph.D., President and COO, have been named EY Entrepreneurs of the Year® 2017 Overall National Award Winners. They were also recognized as the National Award Winners in the Life Sciences category.
“TESARO could not have achieved this honor without the dedicated work of our associates and our strategic partners in advocacy, industry and academia. We are especially grateful to the patients who selflessly participate in our clinical programs, and who with their advocates help us to understand the needs of people living with cancer,” said Dr. Hedley. “We are humbled to accept this award on behalf of our entire TESARO team and we congratulate all of the entrepreneurs who participated in the 2017 national program; their vision and commitment inspire each of us to dream and accomplish more.”
“Thank you to EY and the judges for recognizing TESARO and the important work our team of associates does each day to address the needs of the patients we serve,” said Mr. Moulder. “We founded TESARO with a commitment to building a biopharmaceutical company that strives to put the patient at the center of what we do and because of our passionate and committed associates we have had the privilege of bringing two important new medicines to the cancer community in just seven years.”
As TESARO leaders, Mr. Moulder and Dr. Hedley enable their team to continuously seek out new possibilities to responsibly develop and commercialize innovative cancer treatments. Since its founding in 2010, TESARO has become a leading oncology-focused biopharmaceutical company with more than 750 associates across the U.S. and Europe. With a deep pipeline of new product candidates, TESARO is well positioned to implement our mission and deliver additional meaningful cancer therapies to patients over the next several years.
Earlier this year, Mr. Moulder and Dr. Hedley were recognized as EY Entrepreneurs of the Year in the Life Sciences category for the New England region, which qualified them to be considered for the Entrepreneur of the Year 2017 national program.
To view the full list of this year’s winners, please visit: http://www.ey.com/us/en/about-us/entrepreneurship/entrepreneur-of-the-year.
About EY Entrepreneur of the Year®
EY Entrepreneur of the Year is the world’s most prestigious business award for entrepreneurs. The unique award makes a difference through the way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global award of its kind, Entrepreneur of the Year celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 145 cities in more than 60 countries.
About TESARO
TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com, and follow us on Twitter and LinkedIn.
Investor/Media Contact:
Jennifer Davis
Vice President, Corporate Communications & Investor Relations
+1.781.325.1116 or [email protected]


TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 



